Growth Metrics

Pfizer (PFE) Intangibles (2016 - 2026)

Pfizer has reported Intangibles over the past 18 years, most recently at $52.6 billion for Q1 2026.

  • Quarterly Intangibles fell 2.63% to $52.6 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $52.6 billion through Mar 2026, down 2.63% year-over-year, with the annual reading at $53.7 billion for FY2025, 3.03% down from the prior year.
  • Intangibles was $52.6 billion for Q1 2026 at Pfizer, down from $53.7 billion in the prior quarter.
  • Over five years, Intangibles peaked at $64.9 billion in Q4 2023 and troughed at $28.2 billion in Q4 2022.
  • The 5-year median for Intangibles is $52.6 billion (2026), against an average of $48.4 billion.
  • Year-over-year, Intangibles skyrocketed 72.47% in 2022 and then decreased 14.62% in 2024.
  • A 5-year view of Intangibles shows it stood at $43.4 billion in 2022, then skyrocketed by 49.64% to $64.9 billion in 2023, then fell by 14.62% to $55.4 billion in 2024, then dropped by 3.03% to $53.7 billion in 2025, then fell by 2.18% to $52.6 billion in 2026.
  • Per Business Quant, the three most recent readings for PFE's Intangibles are $52.6 billion (Q1 2026), $53.7 billion (Q4 2025), and $51.3 billion (Q3 2025).